Parathyroid carcinoma is a rare endocrine neoplasm characterized by the malignant proliferation of parathyroid cells capable of causing PTH hypersecretion and, in most cases, an often severe form of PTH-dependent hypercalcemia. Clinically, the disease differs from benign forms of hyperparathyroidism because it is more likely to cause marked hypercalcemia, organ complications related to mineral metabolism abnormalities, and local recurrence, with possible lymph node or distant metastases.
The practical relevance of parathyroid carcinoma derives from the fact that prognosis depends substantially on the quality of the initial operation and on long-term control of hypercalcemia. Diagnostic difficulty arises from its overlap with adenomas or parathyroid tumors of uncertain biological behavior, whereas a definitive diagnosis requires histopathological evidence of invasion or documented metastases. Optimal assessment therefore integrates clinical suspicion, the biochemical profile, localization imaging, and a surgical strategy appropriate to the pre-test probability of malignancy.
The epidemiology of parathyroid carcinoma is dominated by its rarity and by the variability of available estimates, which depend on geographical setting, registry design, the accuracy of histological classification, and distinction from entities with uncertain malignant potential. In clinical practice, carcinoma accounts for a very small proportion of the causes of primary hyperparathyroidism, but its healthcare burden is disproportionate to its frequency because it is more often associated with severe hypercalcemia, organ damage, and the need for repeated surgery or treatment because of recurrence. Sex distribution is less markedly imbalanced than in benign hyperparathyroidism, and diagnosis generally occurs during adulthood, with wide variation among reported series.
Regarding risk factors, a clinically relevant proportion of susceptibility is genetic. A central factor is the CDC73 gene, historically known as HRPT2, which is involved in regulation of the PAF1 complex and transcriptional stability. Loss-of-function alterations are associated with a predisposition to more aggressive parathyroid neoplasms. In some families, carcinoma occurs within the spectrum of hyperparathyroidism-jaw tumor syndrome, in which germline mutations increase the probability of parathyroid lesions with aggressive behavior and make family assessment and molecular characterization crucial when suggested by clinical and histological findings. Somatic CDC73 alterations are also frequent in apparently sporadic disease and are associated with more aggressive biological profiles. Genetics is therefore not an ancillary detail, but a factor that influences surveillance, counseling, and management.
In addition to genetics, several clinical conditions increase the pre-test probability of carcinoma in a patient with hyperparathyroidism. These include markedly elevated calcium levels with symptoms, substantially elevated PTH, advanced skeletal complications, and significant renal involvement, all of which may indirectly indicate more aggressive tumor biology. Although these findings are not specific, their combination can support a more cautious diagnostic and therapeutic strategy and referral to a center experienced in complex endocrine surgery.
An important epidemiological issue concerns diagnostic variability associated with updated histopathological classification. The conceptual transition toward categories such as atypical parathyroid tumor and the emphasis placed on vascular, lymphatic, or perineural invasion and infiltration of adjacent structures influence the number of cases classified as carcinoma and reduce the historical confusion between suspicious lesions and confirmed malignancy. In this setting, accurate case definition is not merely a nosological exercise, but a determinant of appropriate clinical care because it affects follow-up, indications for repeat surgery, and the intensity of surveillance.
Finally, the epidemiological impact of parathyroid carcinoma is influenced by the patient's biological frailty. Advanced age, cardiovascular disease, reduced renal reserve, and osteoporosis increase the clinical consequences of hypercalcemia and make management more complex, because the objective is not only to treat a rare neoplasm but also to prevent acute and chronic events caused by mineral metabolism abnormalities, which are among the main causes of morbidity and, in advanced disease, mortality.
The etiology of parathyroid carcinoma includes sporadic and hereditary forms, with a shared pathogenetic axis centered on the loss of mechanisms that restrict proliferation and invasion by parathyroid cells and on their ability to maintain PTH secretion at levels that are inappropriately high relative to the ionized calcium set point. Under physiological conditions, parathyroid chief cells integrate extracellular signals through the calcium-sensing receptor (CaSR) and rapidly modulate PTH secretion to maintain the stability of the extracellular compartment. In carcinoma, this regulatory system is overridden by a neoplastic program that separates hormone secretion from physiological inhibitory mechanisms and, in many cases, combines endocrine hyperfunction with infiltrative behavior.
At the molecular level, pathogenesis is strongly influenced by alterations in CDC73, which encodes parafibromin, a protein with tumor-suppressor and transcriptional regulatory functions. Loss of function may result from germline or somatic mutations and is associated with loss of nuclear parafibromin immunoreactivity, a finding that may be useful in the diagnostic setting and in triaging patients for genetic investigation. In some cases, tumor biology also involves other pathways, including alterations affecting cell-cycle control and genomic stability, but CDC73 remains conceptually central because it connects hereditary predisposition, histopathological diagnosis, and the risk of recurrence.
The clinical pathophysiology is dominated by the effects of PTH-mediated hypercalcemia and excessive signaling on bone, the kidney, and the vitamin D axis. PTH increases bone resorption by activating remodeling and increasing net resorption, stimulates tubular calcium reabsorption, promotes phosphaturia, and increases renal activation of vitamin D, thereby enhancing intestinal calcium absorption. In parathyroid carcinoma, the magnitude and persistence of these effects may cause marked hypercalcemia, volume depletion, and reduced glomerular filtration, producing a vicious cycle in which dehydration worsens hypercalcemia and hypercalcemia further impairs renal function.
At the skeletal level, accelerated remodeling can lead to bone pain, severe osteopenia, pathological fractures, and osteitis fibrosa cystica, particularly when diagnosis is delayed or when recurrent disease causes uncontrolled hyperparathyroidism. Bone loss is not merely quantitative but also qualitative, because continuous turnover alters microarchitecture and mechanical strength. In advanced cases, effects on muscle and the neuromuscular system become clinically evident, with proximal weakness, fatigability, and an increased risk of falls.
Regarding the kidneys, the combination of hypercalciuria and altered phosphate balance promotes nephrolithiasis and nephrocalcinosis, whereas hypercalcemia-induced afferent vasoconstriction, osmotic polyuria, and dehydration reduce renal function and may precipitate acute kidney injury. Reduced glomerular filtration further worsens hypercalcemia by limiting calcium excretion and makes medical control more difficult during recurrent or metastatic disease.
The cardiovascular component results from both hypercalcemia and its systemic consequences. QT interval shortening, conduction abnormalities, increased vasoconstriction, and susceptibility to arrhythmias may occur, particularly in severe cases, together with hypertension and worsening diastolic function in predisposed individuals. In frail patients, dehydration and hypercalcemia cause hemodynamic instability and mental confusion, transforming a rare endocrine disease into a complex internal medicine emergency.
Finally, the pathophysiology of parathyroid carcinoma includes its capacity for local recurrence, often related to microscopic residual disease or surgical seeding, and its potential for metastatic progression. In many patients, morbidity is more closely related to control of hypercalcemia than to the tumor burden itself, which is why treatment must inseparably integrate oncology and the management of mineral metabolism.
The clinical presentation of parathyroid carcinoma is often driven by hyperparathyroidism that is more clinically apparent than benign disease, with symptoms related to hypercalcemia and organ damage caused by chronic PTH excess. Presentation is highly variable, but a recurrent feature is the presence of multisystem manifestations that evolve over time and may initially be attributed to more common conditions unless an integrated endocrine perspective is maintained. In many patients the course is subacute, with progressive symptoms during the months preceding diagnosis, whereas others may present acutely with a hypercalcemic crisis or renal complications.
The medical history commonly includes marked fatigue, intense thirst and polyuria, constipation, nausea, reduced appetite, and weight loss, often accompanied by diffuse or localized bone pain and proximal muscle weakness. In severe cases, patients may report cognitive decline, irritability, or drowsiness progressing to mental confusion, reflecting both the neurotoxic effects of hypercalcemia and the impact of dehydration. A history of recurrent renal colic or nephrolithiasis may precede the diagnosis, as may low-energy fractures or persistent skeletal pain caused by pathological bone remodeling.
On physical examination, findings may include signs of dehydration, hypotonia, reduced physical performance, and bone tenderness. A palpable neck mass or local compressive symptoms such as dysphonia or dysphagia may be present in a proportion of patients, particularly when the tumor is large or infiltrative. A hard, poorly mobile nodule in the thyroid or parathyroid region associated with marked hypercalcemia increases the pre-test probability of malignancy and supports a more radical surgical approach, although this finding is not consistently present.
Renal manifestations may include polyuria, dehydration, hypertension, and impaired renal function, whereas gastrointestinal involvement may cause abdominal pain, nausea, vomiting, and severe constipation. In some cases, pancreatitis or peptic ulcer disease may complicate the course, particularly when hypercalcemia is marked and persistent. Neuropsychiatric manifestations may include psychomotor slowing, sleep disturbances, and mood instability, with a substantial effect on quality of life.
Symptom severity depends not only on the absolute calcium concentration but also on the rate at which it rises, hydration status, and renal reserve. In older patients or those with comorbidities, nonspecific manifestations such as falls, delirium, or functional decline may be the first indication, making assessment of calcium status essential within diagnostic pathways for frailty. In recurrent or metastatic disease, the clinical picture may similarly be dominated by difficulty controlling hypercalcemia rather than by local tumor symptoms.
Overall, clinical presentation must be interpreted as the result of the interaction between the tumor and the calcium-PTH-vitamin D axis, with a course that may alternate between periods of relative well-being and rapid deterioration, particularly when hypercalcemia worsens or a recurrence is not identified promptly.
Parathyroid carcinoma should be suspected when PTH-dependent hyperparathyroidism exhibits features of biological severity or clinical behavior that are atypical of an adenoma. An initial warning sign is the combination of marked hypercalcemia and very high PTH, particularly when associated with severe symptoms, dehydration, impaired renal function, or advanced skeletal complications. In these circumstances, the objective is not merely to confirm hyperparathyroidism but to estimate the probability of malignancy, because the initial surgical decision has a decisive influence on long-term outcome.
Suspicion increases when classic manifestations of advanced skeletal disease are present, including pathological fractures, persistent bone pain, substantial reduction in bone mineral density, and radiological evidence of severe remodeling, together with multiple renal stones or nephrocalcinosis and deterioration of glomerular filtration. Another clinically relevant finding is a palpable neck mass or local compressive symptoms. Although nonspecific, their presence in association with severe hypercalcemia suggests a larger or more infiltrative lesion.
A setting requiring particular attention is early recurrence after parathyroidectomy or persistent hypercalcemia despite apparently adequate surgery. Although recurrence may occur after incomplete removal of a benign tumor, parathyroid carcinoma has a greater probability of local recurrence, often accompanied by hypercalcemia that is difficult to control. In this setting, reassessment must be rapid and coordinated and should include targeted imaging and specialist multidisciplinary discussion.
A family history and evidence of genetic syndromes further increase suspicion. In patients with familial hyperparathyroidism, ossifying jaw tumors, or features compatible with CDC73-related syndromes, clinical vigilance for parathyroid lesions with aggressive behavior should be heightened. In these patients, surgical timing and extent and postoperative surveillance require a more structured approach than is generally used for typical sporadic disease.
Finally, suspicion should remain high when the clinical and biochemical profile is disproportionate to what would be expected from an adenoma, even when imaging suggests a solitary lesion. Under these circumstances, a prudent strategy is to plan surgery with a team experienced in endocrine oncology, minimizing the risk of capsular rupture and local seeding while maximizing the probability of complete resection during the initial operation.
The diagnosis of parathyroid carcinoma is based on a pathway that begins with confirmation of PTH-dependent hyperparathyroidism and continues with estimation of the probability of malignancy and localization of the lesion, while recognizing that definitive diagnosis is histopathological in most cases. The first laboratory step is to document hypercalcemia with inappropriately elevated PTH, together with assessment of serum phosphate, renal function, vitamin D, and mineral metabolism. In severe cases, evaluation of clinical urgency is also a priority: electrolytes, hydration status, electrocardiography, and evidence of neurological or renal impairment must be considered integral components of the initial assessment.
Once the PTH-dependent nature of hypercalcemia has been established, imaging is used primarily for preoperative localization and surgical planning, not for the definitive distinction between benign and malignant disease. Neck ultrasound can identify the lesion and assess its size, anatomical relationships, and possible infiltration. Functional methods, such as sestamibi scintigraphy or positron emission tomography techniques in selected cases, can assist localization, particularly in recurrent disease or ectopic locations. In suspicious or advanced cases, computed tomography or magnetic resonance imaging of the neck and mediastinum may be useful to define local extension and relationships with adjacent structures. When metastatic staging is indicated, thoracic imaging and targeted assessments are added according to the clinical setting.
Diagnostic assessment of parathyroid carcinoma
A definitive diagnosis requires demonstration of invasion or metastases. According to the most recent World Health Organization classification of parathyroid tumors, decisive findings include unequivocal vascular invasion, lymphatic invasion, perineural invasion, infiltration of adjacent structures, or documented metastases. Histological assessment must therefore be meticulous and, when useful, supported by immunohistochemical markers and integrated interpretation of the clinical and laboratory findings, because some morphological features are suggestive but do not establish malignancy in the absence of invasion.
Fine-needle aspiration biopsy is not a standard strategy for distinguishing adenoma from carcinoma and may be problematic because of the risk of seeding and its limited ability to demonstrate invasion in cytological specimens. The preferred approach is therefore surgical planning appropriate to the level of clinical suspicion, with careful handling and complete resection of the lesion. Postoperatively, a reduction in PTH and calcium supports the effectiveness of surgery, but close surveillance remains necessary because recurrence may develop even after initial biochemical control.
Finally, in patients with a suspected inherited predisposition or a suggestive clinical profile, targeted genetic evaluation, particularly of CDC73, may be appropriate to define personal and familial risk and establish a consistent follow-up strategy. This step is not required automatically for every patient, but becomes important when histological findings or the clinical history suggest an increased risk of recurrence or multifocal disease within the spectrum of predisposing syndromes.
In parathyroid carcinoma, classification begins with the histopathological definition of malignancy and continues with description of the anatomical extent according to shared staging systems. The reference framework is provided by the World Health Organization, which distinguishes carcinoma from lesions of uncertain behavior because the diagnosis of malignancy does not depend solely on cytological atypia or suggestive architectural features, but on demonstration of unequivocal invasion of adjacent tissues, lymphovascular invasion or perineural invasion, and/or the presence of regional or distant metastases. In the absence of these decisive findings, neoplasms with worrisome features fall within the spectrum of atypical tumors or tumors of uncertain malignant potential, according to the terminology used in pathology sources, and require cautious assessment and risk-adapted surveillance.
Once malignancy has been established, anatomical staging provides a common language among endocrinologists, surgeons, pathologists, and oncologists. A formal TNM staging system has been reported for parathyroid carcinoma, in which the T category describes the extent of the primary tumor, the N category describes regional lymph node involvement, and the M category describes distant dissemination. Because the neoplasm is rare, the prognostic performance of stage groupings is less robust than for more common tumors, but TNM remains useful for accurately describing disease anatomy and comparing clinical series and treatment pathways.
TNM categories in parathyroid carcinoma
Stage grouping is derived from the TNM categories and provides a clinically communicable summary of disease extent. In practice, stage should be interpreted together with the probability of complete resection and the degree of achievable biochemical control, because outcomes in parathyroid carcinoma are often determined by the combination of disease anatomy and the severity of the associated hyperparathyroidism.
Stage grouping (I-IV) in parathyroid carcinoma
In addition to staging, histopathological classification is essential because parathyroid carcinoma is a diagnosis that requires evidence of invasion or metastases, whereas some atypical lesions may mimic carcinoma because of fibrosis, connective tissue bands, trabecular growth, mitotic activity, or necrosis without satisfying decisive criteria. In this diagnostic gray area, integration of operative findings, thorough sampling of the capsule and margins, and systematic assessment for lymphovascular or perineural invasion are essential for correct classification.
Regarding prognostic parameters, there is no universally standardized and validated histological grading system comparable to those used for other tumors. Some pathology sources distinguish low-grade and high-grade forms on the basis of cytological and proliferative criteria, but this approach does not replace staging or the assessment of invasion and must not be interpreted as an officially and universally adopted grading system. Parameters such as necrosis, increased mitotic activity, marked pleomorphism, and an increased proliferative index measured by Ki-67 are instead used as supportive findings for risk stratification, integrated with disease anatomy and clinical behavior.
The molecular component represents an additional level of classification, particularly because parathyroid carcinoma is frequently associated with alterations of the CDC73 gene and loss of nuclear parafibromin expression. Immunohistochemical assessment of parafibromin and genetic evaluation when indicated may help clarify difficult diagnoses and guide surveillance, but they do not replace the morphological criteria of malignancy, which remain central.
Finally, a parallel clinical classification integrates the endocrine and metabolic dimension, because the severity of parathyroid carcinoma is often determined by the degree of hypercalcemia, associated organ damage, and refractoriness of biochemical control, in addition to oncological extent. In many clinical series, the feasibility of complete resection during the initial operation and the ability to maintain stable long-term control of mineral metabolism are major determinants of outcome, making an integrated interpretation of staging, histology, and biochemical behavior essential.
The primary objective of parathyroid carcinoma treatment is complete resection during the initial operation, because the probability of durable control is greatest when the tumor is removed radically, without capsular rupture, and with adequate margins. When preoperative suspicion is high, the preferred surgical approach is en bloc resection of the lesion together with adjacent tissues that are involved or at risk, often including the ipsilateral thyroid lobe when required to ensure local radicality, while preserving critical structures when they are not infiltrated. This principle derives from the observation that limited or fragmented operations increase the risk of persistent or recurrent local disease, making subsequent control more difficult.
Intraoperative management should prioritize careful dissection and minimal manipulation of the tumor to reduce the risk of seeding. Lymph node assessment does not automatically follow the extent used for other neck malignancies. The indication for lymph node dissection is guided by clinically or radiologically suspicious nodes rather than routine prophylactic dissection, and the strategy must be individualized according to disease extent and overall surgical risk.
In recurrent or metastatic disease, surgery retains a central role as a form of disease control, particularly when recurrence is resectable and reducing the burden of hormone-secreting tissue improves control of hypercalcemia. However, the risk of complications increases with repeated operations, particularly recurrent laryngeal nerve injury and swallowing disorders. The decision must therefore balance metabolic benefit against functional risk. In selected patients, repeated procedures may be necessary to maintain calcium concentrations within an acceptable range and prevent cumulative organ damage.
Medical therapy is essential in two settings: preoperative stabilization of hypercalcemia and control of hypercalcemia in unresectable or recurrent disease. Hydration with saline solution, correction of electrolyte abnormalities, and medications that reduce bone resorption are fundamental measures. Intravenous bisphosphonates reduce calcium release from bone, whereas denosumab may be useful when renal impairment limits the use of bisphosphonates or when hypercalcemia is refractory. Close monitoring is required because of the risk of hypocalcemia, particularly if bone turnover decreases rapidly. Cinacalcet, a modulator of the calcium-sensing receptor, reduces PTH secretion and serum calcium and may be central to chronic control of hypercalcemia in advanced disease, although it is not an antitumor treatment in the strict sense.
The role of adjuvant radiotherapy remains selective and controversial. In some settings with a high risk of local recurrence or unresectable microscopic residual disease, it may be considered as a strategy for locoregional control, but it does not replace radical surgery when complete resection is feasible. In metastatic disease, evidence supporting systemic treatments is limited and these treatments are generally reserved for selected patients, often with the objective of controlling progression or indirectly reducing hypercalcemia. Management requires a center with specific expertise and multidisciplinary assessment.
A cross-cutting aspect of treatment is the prevention and management of hungry bone syndrome after resection of a highly secretory tumor. A rapid fall in PTH may cause intense uptake of calcium and phosphate by the recovering skeleton, leading to prolonged hypocalcemia that requires calcium supplementation, active vitamin D, and close monitoring. This phenomenon is not a marginal complication but a determinant of perioperative safety and quality of recovery, particularly in patients with severe preoperative skeletal disease.
Follow-up is a structural component of care for parathyroid carcinoma because the disease may recur even after an apparently radical initial operation and because clinical risk is often determined by the reappearance of hypercalcemia. Monitoring must therefore integrate endocrine and metabolic assessment with local and systemic oncological surveillance, with closer follow-up during the first years and subsequent adjustment according to biochemical stability and the individual risk profile.
The cornerstone of laboratory follow-up is serial measurement of serum calcium and PTH, together with creatinine, phosphate, and, when useful, vitamin D. Recurrent hypercalcemia with elevated PTH is often the first sign of functional recurrence and may precede radiological evidence. Biochemical surveillance is therefore not merely a routine examination but an early warning system that allows prompt activation of targeted imaging and surgical assessment while disease may still be resectable.
Regarding imaging, neck ultrasound is useful for locoregional surveillance, whereas functional imaging and computed tomography or magnetic resonance imaging are reserved for suspected recurrence, progressive increases in PTH or calcium, or clinical signs compatible with advanced disease. In recurrent disease, the choice of imaging should be guided by its probability of identifying resectable lesions and by the postoperative anatomical setting, in which scarring and altered anatomy may reduce the sensitivity of some techniques.
Follow-up must include assessment of outcomes involving the kidneys and skeleton. Renal function, a history of nephrolithiasis, and renal imaging when indicated are part of surveillance, particularly in patients with previous severe or prolonged hypercalcemia. Regarding the skeleton, bone densitometry and fracture-risk assessment are relevant both for quantifying preoperative damage and for documenting recovery after normalization of PTH, recognizing that skeletal reconstruction requires time and that postoperative hypocalcemia may be prolonged in patients with hungry bone syndrome.
Another essential component is surveillance for functional complications related to repeated operations, particularly dysphonia, dysphagia, and impaired cervical mobility, which may progressively worsen with multiple procedures. Integrated management with speech and voice specialists, nutrition professionals, and rehabilitation services may be required to maintain quality of life, particularly in recurrent disease where the realistic objective is prolonged control rather than definitive cure.
Finally, in patients with suspected or confirmed genetic predisposition, follow-up must include counseling and surveillance pathways consistent with familial risk. This does not mean applying uniform protocols, but adapting monitoring intensity and intervention thresholds to the probability of recurrence and the presence of phenotypes associated with the genetic syndrome, together with clear and continuous communication with the patient.
The prognosis of parathyroid carcinoma is heterogeneous and depends critically on the completeness of the initial operation, the presence of local invasion or metastases, and, above all, the ability to maintain long-term control of hypercalcemia. Many patients experience a prolonged course with intermittent recurrences, during which survival may be long but require repeated operations and treatments. In this setting, the clinical objective is not limited to measuring survival, but includes preventing cumulative organ damage and maintaining an acceptable quality of life through stable metabolic control.
The most clinically relevant complications are associated with disturbed mineral metabolism. Persistent or recurrent hypercalcemia may cause progressive kidney failure, nephrocalcinosis, recurrent nephrolithiasis, and susceptibility to hypercalcemic crises with neurological abnormalities and hemodynamic instability. In the skeleton, persistent elevation of PTH accelerates remodeling and increases the risk of fractures, chronic pain, and disability, whereas muscle weakness and reduced physical performance increase the risk of falls and frailty.
Surgical complications become increasingly important as the number of repeated operations rises. Injury to the recurrent laryngeal nerve, dysphonia, dysphagia, and complex neck scarring may accumulate over time and become major determinants of quality of life, even when biochemical control is partially achieved. Multiple recurrences also lead to increasingly difficult procedures with a higher risk of complications than the initial operation. Referral to experienced centers and careful planning are therefore indirect but substantial prognostic factors.
A specific issue is the postoperative metabolic complication known as hungry bone syndrome, which is more likely after resection of highly secretory tumors and in patients with severe skeletal disease. Hypocalcemia may be profound and prolonged and may require intensive supplementation and frequent monitoring. Although manageable, this complication may prolong hospitalization and significantly affect recovery, making preoperative risk assessment and a postoperative replacement plan necessary.
In metastatic or unresectable disease, prognosis is often determined more by control of hypercalcemia than by tumor growth. Refractory hypercalcemia is one of the main causes of clinical deterioration, and management requires a combination of cinacalcet, antiresorptive therapies and, when feasible, surgical reduction of hormone-secreting tissue. In this setting, functional prognosis depends on the ability to maintain serum calcium within a range that preserves renal function, neurological function, and physical performance.
Overall, parathyroid carcinoma is a rare but clinically demanding neoplasm. The best outcome is achieved when suspicion arises early, the initial surgery is appropriate, and follow-up is rigorous and focused on biochemical control and prevention of organ complications.